Full-Genome Analysis of Avian Influenza A(H5N1) Virus from a Human, North America, 2013

Kanti Pabbaraju, Raymond Tellier, Sallene Wong, Yan Li, Nathalie Bastien, Julian W. Tang, Steven J. Drews, Yunho Jang, C. Todd Davis, Kevin Fonseca, and Graham A. Tipples

Full-genome analysis was conducted on the first isolate of a highly pathogenic avian influenza A(H5N1) virus from a human in North America. The virus has a hemagglutinin gene of clade 2.3.2.1c and is a reassortant with an H9N2 subtype lineage polymerase basic 2 gene. No mutations conferring resistance to adamantanes or neuraminidase inhibitors were found.

Since the 1997 emergence of highly pathogenic avian influenza (HPAI) A(H5N1) virus in Hong Kong, China, 648 HPAI A(H5N1) infections and 384 associated deaths in humans have been reported. During 2013, Cambodia reported the most human infections, followed by Egypt, Indonesia, China, and Vietnam (www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/, December 10, 2013, report). In December 2013, an HPAI A(H5N1) infection was reported in a Canadian resident who recently returned from China. No human or poultry HPAI A(H5N1) infections had been previously reported in North America.

Case Report and Laboratory Investigations

Preliminary details of this case have been reported (1) (online Technical Appendix 1, wwwnc.cdc.gov/EID/article/20/5/14-0164-Techapp1.pdf). The patient initially sought care for respiratory symptoms; however, the probable cause of death was listed as meningoencephalitis, an unusual outcome for HPAI A(H5N1) infections in humans. Detailed interviews with close contacts have not identified exposure to infected avian sources or environmental contamination, although these investigations are continuing. Because symptom onset occurred during a return flight from China, it is probable that the patient was exposed to the virus while in China.

Nasopharyngeal swab (NP) samples, bronchoalveolar lavage (BAL), and cerebrospinal fluid (CSF) samples tested positive for influenza A(H5N1) virus by various molecular testing methods, including sequencing, at the Provincial Laboratory for Public Health and the National Microbiology Laboratory, Public Health Agency of Canada (1). An isolate cultured from BAL (A/Alberta/01/2014) underwent full-genome sequencing (methods available in online Technical Appendix 1); analysis results are presented here.

Partial sequences of virus from the primary specimens (shown in parentheses) included 1,378 bp of the hemagglutinin (HA) gene (CSF, BAL, NP), 1,350 bp of the neuraminidase gene (BAL), 810 bp of the matrix gene (NP), and 687 bp of the polymerase basic 2 (PB2) gene (NP). These sequences were identical to corresponding sequences obtained from the isolate, suggesting the absence of cell culture–induced changes.

BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) analysis of each gene of A/Alberta/01/2014 showed that 7 of 8 genes shared ≥99% identity at the nucleotide and protein levels with HPAI A(H5N1) viruses of avian origin. However, the PB2 gene showed 98% nt similarity and 99% aa identity to avian influenza A(H9N2) viruses collected in China. Phylogenetic analysis of each gene (online Technical Appendix 2, wwwnc.cdc.gov/EID/article/20/5/14-0164-Techapp2.pdf) with sequences from related viruses confirmed that only the PB2 gene resulted from reassortment with an avian influenza A virus containing an H9N2 subtype lineage PB2 gene (Figure 1). Phylogenetic analysis of the HA gene demonstrated that the virus belongs to clade 2.3.2.1c (2) (Figure 2), which has been detected in many countries and has recently been reported in China, Vietnam, and Indonesia (2). The HA gene of A/Alberta/01/2014 (H5N1) was most closely related to the sequence of an HPAI A(H5N1) virus from a tiger that died in 2013 at a zoo in Jiangsu, China. This combination of clade 2.3.2.1c lineage HA, neuraminidase, and internal gene segments derived from influenza A(H5N1) viruses and an H9N2 subtype lineage PB2 gene indicated that this virus is a previously undescribed genotype of HPAI A(H5N1).

To assess the virus for molecular markers of pandemic risk, we reviewed all protein sequences listed in the H5N1 Genetic Changes Inventory (3). The HA protein possessed a multibasic amino acid cleavage site motif (PQRERRRRKR*G) similar to other clade 2.3.2.1 viruses.
The sequence of the 220-loop receptor binding site (RBS) contained the typical avian amino acids, Q222/G224, predictive of a preference for the avian α2,3 rather than the human α2,6 sialic acid (SA) host cell receptor (5); all HA gene numbering is based on H5 viruses unless otherwise indicated. The RBS sequence was identical in the NP and BAL samples, suggesting the absence of adaptive changes in the cultured isolate. The G221R substitution, uncommon in HPAI A(H5N1) virus, was detected in the RBS. Previously reported in a clade 2 HPAI A(H5N1) virus (GenBank accession no. ABR13964), R221 has been shown in influenza A/H3 (R225 by H3 numbering) to slightly increase binding to human erythrocytes (6). Other mutations of interest in A/Alberta/01/2014 were D94N, S133A, S155N, and T156A. D94N decreased binding to α2,3 SA and increased it to α2,6 SA in a pseudotyping assay (7).
and glycan array assays (8). When together, S155N and T156A also increased binding to α2,6 SA (assayed with resiallated erythrocytes). T156A abrogates a N-glycosylation site and, when together with S223N (not found in A/Alberta/01/2014), may improve virus replication in the upper respiratory tract of ferrets (9); T156A is consistently found in ferret-adapted mutants capable of airborne transmission (5). The collective effects of all these mutations and their phenotypic manifestations are unclear.

Comparison of the HA amino acid sequence of A/Alberta/01/2014 with that of the nearest H5N1 clade 2.3.2.1 highly pathogenic avian influenza A(H5N1) viruses with A/Alberta/01/2014 (GISAID accession no. EPI500771). The avian influenza A(H5N1) virus detected in Canada is underlined. The nearest reassortant World Health Organization candidate vaccine viruses (CVV) for each group of clade 2.3.2.1 are denoted by CVV. Asterisks indicated viruses collected in 2012–2014. Amino acid differences at branch nodes indicate HA1 substitutions relative to the nearest CVV for clade 2.3.2.1 viruses (5). T156A and other mutations are consistently found in ferret-adapted mutants capable of airborne transmission (5). The collective effects of all these mutations and their phenotypic manifestations are unclear.

Comparison of the HA amino acid sequence of A/Alberta/01/2014 with that of the nearest H5N1 clade 2.3.2.1 highly pathogenic avian influenza A(H5N1) viruses with A/Alberta/01/2014 (GISAID accession no. EPI500771). The avian influenza A(H5N1) virus detected in Canada is underlined. The nearest reassortant World Health Organization candidate vaccine viruses (CVV) for each group of clade 2.3.2.1 are denoted by CVV. Asterisks indicated viruses collected in 2012–2014. Amino acid differences at branch nodes indicate HA1 substitutions relative to the nearest CVV for clade 2.3.2.1 viruses (5). T156A and other mutations are consistently found in ferret-adapted mutants capable of airborne transmission (5). The collective effects of all these mutations and their phenotypic manifestations are unclear.

Comparison of the HA amino acid sequence of A/Alberta/01/2014 with that of the nearest H5N1 clade 2.3.2.1c highly pathogenic avian influenza A(H5N1) viruses with A/Alberta/01/2014 (GISAID accession no. EPI500771). The avian influenza A(H5N1) virus detected in Canada is underlined. The nearest reassortant World Health Organization candidate vaccine viruses (CVV) for each group of clade 2.3.2.1c are denoted by CVV. Asterisks indicated viruses collected in 2012–2014. Amino acid differences at branch nodes indicate HA1 substitutions relative to the nearest CVV for clade 2.3.2.1c viruses (5). T156A and other mutations are consistently found in ferret-adapted mutants capable of airborne transmission (5). The collective effects of all these mutations and their phenotypic manifestations are unclear.
In agreement with Xu et al. (4), no mutations conferring reduced susceptibility to neuraminidase inhibitors were identified for clade 2.3.2.1. The predicted amino acid sequence of the M2 protein did not reveal any changes associated with reduced susceptibility to adamantanes (10). Mutation V27I was found, but its significance is uncertain. Mutations N30D and T215A found in the M1 gene of A/Alberta/01/2014 were associated with increased virulence in mice. The cumulative effect of these changes may result in increased lethality (11).

The PB2 sequence showed the presence of E627 in both the primary specimen and isolate, establishing the lack of a well-known mammalian adaptation motif (5, 12). Amino acid changes L89V, G309D, T339K, R477G, I495V, and K627E and a change to Met at the predicted position A676T (13) were noted in the A/Alberta/01/2014 isolate. These PB2 substitutions in conjunction with changes in the M1 and HA proteins (only some of which were identified) have been described to enhance polymerase activity and virulence in mice. Experiments in mice also demonstrated that compensatory amino acid substitutions in PB2 can rescue polymerase activity in K627E mutants (13). Lethal HPAI A(H5N1) isolates, such as A/Quail/36/04, show the presence of E627, suggesting that compensatory mutations are possible in PB2 and other genes (14). The PB1 protein showed the P598L mutation reported to enhance polymerase activity in mammalian cells and mice (3). This change has been reported to enhance the polymerase activity of an attenuated human virus carrying the PB2 K627E mutation (15). Of the polymerase mutations hypothesized to increase the RNA polymerase activity of HPAI A(H5N1) viruses, namely P149S, R226H, K357I, and T515S, only two, 149S and 357T, were present in the A/Alberta/01/2014 isolate (3).

Mutations in the nucleoprotein gene reported to enhance replication efficiency, virulence, and transmission (3) were absent in the isolate. Several NS1 mutations reported to increase virulence in mice were present in A/Alberta/01/2014: P42S, D87E, L98F, and I101M; a 4-bp deletion from nt 80–84, along with the D92E shift; and the PDZ ligand domain (ESEV) at the C terminus (3). This change has been reported to enhance the polymerase activity of an attenuated human virus carrying the PB2 K627E mutation (15). Of the polymerase mutations hypothesized to increase the RNA polymerase activity of HPAI A(H5N1) viruses, namely P149S, R226H, K357I, and T515S, only two, 149S and 357T, were present in the A/Alberta/01/2014 isolate (3).

Mutations in the nucleoprotein gene reported to enhance replication efficiency, virulence, and transmission (3) were absent in the isolate. Several NS1 mutations reported to increase virulence in mice were present in A/Alberta/01/2014: P42S, D87E, L98F, and I101M; a 4-bp deletion from nt 80–84, along with the D92E shift; and the PDZ ligand domain (ESEV) at the C terminus (3). This change has been reported to enhance the polymerase activity of an attenuated human virus carrying the PB2 K627E mutation (15). Of the polymerase mutations hypothesized to increase the RNA polymerase activity of HPAI A(H5N1) viruses, namely P149S, R226H, K357I, and T515S, only two, 149S and 357T, were present in the A/Alberta/01/2014 isolate (3).

Conclusion

Analysis of the whole genome of HPAI A(H5N1) virus provides valuable insight into the presence of mutations that may reflect adaptive changes, altered virulence, and/or transmission phenotype. Because of the unique manifestation of neurologic symptoms and encephalitis reported in this patient, additional studies are needed to understand the broader aspects of virus heterogeneity and its role in this fatal case.

Acknowledgments

We gratefully acknowledge the tremendous work of the clinical and public health teams in Alberta involved in the management and follow-up of this case and deeply appreciate the cooperation of the family during the investigation of this tragic event. We thank the technical laboratory staff for their work and contributions to the confirmation and analysis of this influenza strain. We greatly appreciate and acknowledge the generous discussions and expert input of Nancy Cox and her team at the US Centers for Disease Control and Prevention.

Ms Pabbaraju is a senior laboratory scientist at the Provincial Laboratory for Public Health. Her research focuses on the development of diagnostic tests for viral and bacterial pathogens as well as studies on the epidemiology of viruses.

References


Address for correspondence: Kevin Fonseca, Provincial Laboratory for Public Health, 3030 Hospital Dr NW, Calgary, AB T2N 4W4, Canada; email: kevin.fonseca@albertahealthservices.ca
Full-Genome Analysis of Avian Influenza A(H5N1) Virus from a Human, North America, 2013

Technical Appendix 1

Case Details

The individual, a young adult accompanied by a family member, left Canada for China on December 6, 2013, and was exclusively in Beijing, in urban locations. There was no reported contact with live poultry, visits to wet markets or handling of fresh poultry.

During the return flight on December 27, 2013, the individual experienced symptoms of malaise, chest pain, and fever and presented to the local Emergency Department on December 28, 2013. The complete blood count (CBC) showed a total white blood count (wbc) of $12.6 \times 10^9$ cells/L (reference range $4.0–10.0 \times 10^9$ cells/L) with raised neutrophils ($11.1 \times 10^9$ cells/L) and low lymphocytes ($0.8 \times 10^9$ cells/L). A chest x-ray and CT scan revealed a right apical infiltrate; a diagnosis of pneumonia was made, the patient was prescribed levofloxacin and discharged home.

The individual returned to the same Emergency Department on January 01, 2014, now with worsening pleuritic chest pains and shortness of breath, a mild headache, exacerbated by head movement, right upper quadrant and epigastric pain, nausea and vomiting with no diarrhea. A chest x-ray showed a multi-lobar pneumonia, with moderate effusion, reflecting significant progression when compared with the x-ray from the first ED visit. A thoracentesis, performed while in the ED, revealed a dark amber cloudy fluid that was sterile in bacterial culture. The CBC again showed a wbc count of $10.2 \times 10^9$ cells/L, neutrophil count of $9.5 \times 10^9$ cells/L, platelet count within the normal range, normal ALT, slightly elevated AST at 46U/L (reference range 7–40U/L) and LDH at 288U/L (reference range 100–225U/L).
Admission to a general medicine ward for investigation was facilitated and treatment was initiated with intravenous piperacillin-tazobactam. On January 2, 2014 the individual reported visual changes and on-going headache, and coupled with increasing oxygen requirements was admitted to the ICU for intubation and ventilation. Early in the morning of January 3rd, the individual developed a sudden episode of tachycardia and severe hypertension followed by hypotension requiring inotropic support. At this stage, pupils were dilated and there was no response to pain.

A CT brain suggested diffuse encephalitis and intracranial hypertension; the neurologic examination was consistent with brain death. A MRI/MRA showed significant generalized edema, evidence of meningitis and ventriculitis and significant reduction in cerebral blood flow. A lumbar puncture was performed after brain death determination and before removal of ventilatory and inotropic support.

**Methods**

**Samples**

Nasopharyngeal swabs (NP) and broncho-alveolar lavage (BAL) were sent to the Provincial Laboratory for investigation of influenza and other respiratory viral agents. The cerebrospinal fluid (CSF) was sent for testing of the herpesvirus group, enterovirus and parechoviruses. Two NP swabs, CSF and BAL initially tested positive for influenza A by RT-PCR targeting the M gene, subsequently determined to be H5 subtype by real-time RT-PCR with viral titers conducive for direct sequencing (1). Sequence data was obtained directly from the patient samples and compared to the cultured isolate for the following specimen types and gene targets: Matrix from the NP, neuraminidase from the BAL, hemagglutinin from the CSF, BAL and NP and polymerase B2 subunit from the NP based on availability of patient specimen and nucleic acid extracts.

Our preliminary findings were subsequently confirmed by the National Microbiology Laboratory (NML) that this strain was an avian influenza A(H5N1).

**Isolation of influenza A H5N1 in cell culture**

For virus propagation, 10 μL of the BAL specimen was inoculated into the Madin-Darby canine kidney cell line (MDCK) (CCL34, American Type Culture Collection, Rockville, Md.)
and examined for cytopathic effect. The MDCK cells were maintained in Eagles’s MEM containing 100U/mL Penicillin, 100 μg/mL Streptomycin, 0.292 mg/mL Glutamine, 25mM Hepes buffer, 0.1 mM MEM nonessential amino acid, 1 mM MEM sodium pyruvate and 2 μg/mL TCPK-trypsin. Cells were incubated at 37°C in a CO2 incubator and observed daily for cytopathic effect (World Health Organization. Global Influenza Surveillance Network. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011. http://whqlibdoc.who.int/publications/2011/9789241548090_eng.pdf). Influenza A(H5N1) virus was confirmed by real-time RT-PCR. The isolate was designated as A/Alberta/01/2014.

Full genome Sanger sequencing from the BAL isolate

Reactions were performed using BigDye-Terminator v3.1 Cycle Sequencing Reaction Kit on a 3730 xl Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s instructions. The A/Alberta/01/2014 virus was bi-directionally sequenced across all segments using a combination of in-house and a universal primer sets for the full-length amplification of the genome (1). Sequences were assembled, curated, and edited using Sequencher 5.2.3 (Gene Codes Corporation, Ann Arbor, MI, USA). All sequences have been submitted to the Global Initiative on Sharing Avian Influenza Data (GISAID) (PB2: EPI500778; PB1: EPI500777; PA: EPI500776; HA: EPI500771; NP: EPI500774; NA: EPI500773; MP: EPI500772; NS: EPI500775).

Partial Sanger sequencing directly from specimen

All amplifications were performed using the QiagenOneStep RT-PCR kit (Qiagen, Mississauga, Ontario, Canada). Bi-directional Sanger sequencing was performed using the BigDye® Terminator v3.1 Cycle Sequencing Kit and the BigDyeXTerminator® Purification kit (Life Technologies, Burlington, Ontario, Canada) on the 3500xl Genetic Analyzer (ABI). Sequence analysis was performed using Seqscape v2.7 and Sequencing Analysis SeqA6 (ABI), sequence alignments were performed using Clustal W (BioEdit). Primers used to amplify the different gene segments from the primary specimen can be provided upon request.

Phylogenetic analysis

Full length sequences of each gene segment were aligned to closely related sequences identified through BLAST searches in publicly available influenza sequence databases and previously generated gene segment alignments. Trees were built with MEGA5 software using
the Neighbor-Joining method based on a maximum composite likelihood model and mid-point rooted. The reliability of the trees was estimated by bootstrap re-sampling analysis with 1,000 replications.

Reference

Full-Genome Analysis of Avian Influenza A(H5N1) Virus from a Human, North America, 2013

Technical Appendix 2
Figure. Neighbor-joining phylogenetic trees of the polymerase basic 1 (PB1) (GSAID accession no. EPI500777), polymerase (PA) (GSAID accession no. EPI500776), nucleoprotein (NP) (GSAID accession no. EPI500774), neuraminidase (NA) (GSAID accession no. EPI500773), matrix (M) (GSAID accession no. EPI500772), and nonstructural protein (NS) (GSAID accession no. EPI500775) genes of highly pathogenic avian influenza A(H5N1) viruses with A/Alberta/01/2014. The H5N1 virus detected in Canada is underlined. Bootstraps generated from 1,000 replicates are shown at branch nodes. Scale bar represents nucleotide substitutions per site. GSAID, Global Initiative on Sharing Avian Influenza Data.